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rectile Dysfunction
he New Harbinger for Major Adverse
ardiac Events in the Diabetic Patient*
obert A. Kloner, MD, PHD, FACC
os Angeles, California
rectile dysfunction (ED) was once thought of as a primar-
ly psychological problem. Although this is true in some
en, in the majority of men over the ages of 40 to 50 the
roblem is likely due to vascular disease, including the early
tage of atherosclerosis, specifically endothelial dysfunction.
f the blood vessels that supply blood to the corpora
avernosa of the penis cannot dilate in response to the
ppropriate signals, then an erection will not occur. Many of
he risk factors for ED are the same as for other vascular
iseases (such as coronary artery disease [CAD]) and
nclude smoking, hypertension, dyslipidemia, diabetes, as
ell as lack of physical activity and obesity (1). Thus men
ith ED over the age of 40 commonly have some of these
isk factors.
See pages 2040 and 2045
A further development in the link between ED and
ardiovascular disease has come from recent reports that ED
ight be a harbinger for major adverse cardiovascular
vents. Furthermore, ED remains a risk factor for develop-
ng these adverse cardiac events even after correcting for
ther known cardiovascular risk factors.
A classic study regarding this topic was published by
hompson et al. (2). As part of the Prostate Cancer
revention Trial, men age 55 years or older who were part
f a placebo group (n  9,457) were evaluated at 3-month
ntervals for ED and cardiovascular disease. There were
,247 men with no ED at study entry; 2,420 developed
ncident ED over 5 years. Incident ED (adjusted for other
ardiovascular risk factors) was associated with a hazard
atio (HR) of 1.25 (95% confidence interval [CI] 1.02 to
.53; p  0.04) for subsequent cardiovascular events (in-
luding myocardial infarction, coronary revascularization,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Heart Institute, Good Samaritan Hospital, Division of Cardiovascularw
edicine, Keck School of Medicine, University of Southern California, Los Angeles,
alifornia. Dr. Kloner is a speaker/consultant for Pfizer and Lilly.erebrovascular accident, transient ischemic attack, conges-
ive heart failure, fatal cardiac arrest, or nonfatal cardiac
rrhythmia requiring treatment). The adjusted HR was even
igher (1.45; 95% CI 1.25 to 1.69; p 0.001) for men with
ither incident or prevalent ED (i.e., had ED at study
ntry). The authors stated that incident ED “had an equal or
reater effect on subsequent cardiovascular events of the
ame magnitude as a family history of myocardial infarction,
igarette smoking, or measures of hyperlipidemia” (2).
Blumentals et al. (3) studied the association between ED
nd myocardial infarction as part of a managed care data-
ase. There were 12,825 men with ED who were compared
ith an equal number without ED followed for almost 5
ears. Those with ED had a 2-fold increased risk for acute
yocardial infarction after adjusting for a number of con-
ounding risk factors.
Both our group (4) and Montorsi et al. (5) showed that
he prevalence of ED was high among men with known
AD. In the Montorsi et al. (5) study of 300 consecutive
atients with acute chest pain and angiographically docu-
ented CAD, the prevalence of ED was 49%. Of 147
atients with both ED and CAD, the ED symptoms
ecame clinically manifest before the CAD symptoms in
7% of patients, with a mean time interval between onset of
D and clinical symptoms of CAD of 39 months. Of note
nd relevant to the reports by Gazzaruso et al. (6) and Ma
t al. (7) in this issue of the Journal is that in the Montorsi
t al. (5) study all patients that had type 1 diabetes, ED, and
AD developed ED before symptoms of CAD.
The present issue of the Journal contains 2 complementary
rticles (6,7) that extend our knowledge of the link between
D and subsequent cardiovascular events. Gazzaruso et al. (6)
ecruited 291 type 2 diabetic males with silent CAD.
Those patients who developed major adverse cardiac
vents over the course of approximately 47 months were
ore likely to have ED (61.2%) versus those who did not
36.4%). On multivariate analysis, ED remained an impor-
ant predictor of major adverse cardiac events. The authors
oint out that, although it is already known that diabetic
atients have a high risk of cardiovascular disease, the risk is
ven higher in those diabetic patients that develop ED.
The article by Ma et al. (7) in this issue of the Journal
tudied a cohort of 2,306 diabetic men with no clinical
vidence of CAD. At baseline 27% had ED. Over the
ourse of approximately 4 years, the incidence of coronary
eart disease was greater in men with ED (19.7/1,000
erson-years) compared with those without ED (9.5/1,000
erson-years). After adjustments for other covariates, age,
uration of disease, antihypertensive agents, and albumin-
ria, ED remained an independent predictor of coronary
eart disease (HR 1.58, 95% CI 1.08 to 2.30, p  0.018).
Thus, both of these important studies suggest that in
iabetic patients ED is a predictor of future cardiovascular
vents. Of course, this same statement might be true of a
ider population of patients, as suggested by the other
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Editorial Comment May 27, 2008:2051–2tudies (1,3,5), but might be especially relevant to the
iabetic population where ED is common, as is silent
yocardial ischemia. Hence, physicians seeing diabetic
atients should ask about ED and aggressively treat cardio-
ascular risk factors that these patients might have—
ncluding dyslipidemia and hypertension.
Why does ED seem to precede symptoms of CAD in
atients with a vascular etiology for ED? Montorsi et al. (8)
uggests that this phenomenon relates to the size or diam-
ter of the blood vessels. For example, the penile artery has
 diameter of 1 to 2 mm, whereas the proximal left anterior
escending coronary artery is 3 to 4 mm in diameter. An
qually sized atherosclerotic plaque burden in the smaller
enile arteries would more likely first compromise flow and
ause ED compared with the same amount of plaque in the
arger coronary artery causing angina. Another possibility,
aised by Ma et al. (7), is that endothelium-dependent and
ndothelium-independent vasodilation are impaired in the
iabetic patient before the onset of overt CAD. Impaired
asodilation without an anatomic atherosclerotic plaque
arrowing the lumen of a penile artery is perhaps more
ikely to lead to ED than the same scenario in the coronary
rteries leading to symptoms of angina.
Interesting features of the Gazzaruso et al. (6) study relate
o the pharmacologic intervention received by the patients.
n their study, statin use significantly reduced major adverse
ardiac events. This observation is not unexpected. Recent
arge clinical trials such as the CARDS (Collaborative
torvastatin Diabetes Study) trial showed that, even with a
aseline low-density lipoprotein of approximately 117
g/dl, 10 mg atorvastatin significantly reduced the inci-
ence of nonfatal myocardial infarctions and strokes in
iabetic patients (9). The surprising and somewhat hopeful
ew finding in the Gazzaruso et al. (6) study was the
bservation that there was a trend for phosphodiesterase
ype 5 (PDE5) inhibitor use to be associated with a lower
ate of major adverse cardiac events (although this fell just
hort of being statistically significant). Gazzaruso et al. (6)
eviews some of the potential mechanisms for a benefit of
DE5 inhibitors on the cardiovascular system, including an
mprovement in endothelial dysfunction. In addition, pos-
ible direct cardioprotective effects of the PDE5 inhibitors
n ischemic/reperfused myocardium have now been de-
cribed. Kukreja et al. (10,11) suggested that both sildenafil
nd vardenafil were capable of reducing myocardial infarct
ize in experimental animal models. Although sildenafil did
ot reduce anatomic myocardial infarct size in our rabbit
odel of 30 min of ischemia/reperfusion, it did have certain
eneficial hemodynamic effects: reducing left ventricular
nd-diastolic pressure during ischemia, and reducing the
schemic bed’s vascular resistance after ischemia/reperfusion
12). We did observe, in a rat model of coronary artery
cclusion and reperfusion, a significant reduction in myo-
ardial infarct size with the long-acting PDE5 antagonist
adalafil (13).The pre-clinical results and findings of the study by
azzaruso et al. (6) suggest the need for a long-term,
andomized, placebo-controlled trial of PDE5 inhibitors in
atients with risk factors for CAD in which end points are
ajor adverse cardiac events. Although the PDE5 inhibitor
ildenafil was initially studied as an antianginal agent and
hen went on to become approved for the treatment of ED
nd recently for pulmonary hypertension, study of the
DE5 inhibitors has come full circle. With evidence that
DE5 inhibitors improve endothelial function, slightly
educe blood pressure, and might have a primary cardiopro-
ective effect, the time has come to study these agents
ystematically as potential therapies for the prevention of
dverse cardiac events in patients with vascular risk factors.
eprint requests and correspondence: Dr. Robert A. Kloner, Heart
nstitute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los
ngeles, California 90017. E-mail: rkloner@goodsam.org.
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